SLC5A2 and chronic kidney disease: For moderate and advanced CKD Stages 3–4, personalized conservative treatment is recommended, often with a low-protein diet (0.55–080 g/kg body weight/day), HDP and lifestyle, avoidance of nephrotoxic medications, and renoprotective medications, including a renin-angiotensin system modulator (Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II Receptor Blockers (ARB) and Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor, to manage symptoms and slow CKD progression to prevent or delay ESRD [5,6,7,8,9,28].